Antibody-based antiangiogenic cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 9, Issue 6, 2005, Pages 1235-1245

  Sanz, Laura ^a   Álvarez Vallina, Luis ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Angiogenesis; Antibody; Cancer

Indexed keywords

ABCIXIMAB; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; BEVACIZUMAB; INTERLEUKIN 12; M 200; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2C3; MONOCLONAL ANTIBODY 3D8; MONOCLONAL ANTIBODY CDP 791; MONOCLONAL ANTIBODY CNTO 95; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY IMC 1121B; MONOCLONAL ANTIBODY IMC 18F1; MONOCLONAL ANTIBODY IMC 1C11; MONOCLONAL ANTIBODY L19; MONOCLONAL ANTIBODY L36; MONOCLONAL ANTIBODY LM 609; NAKED DNA; PLASMID DNA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TECHNETIUM 99M; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VOLOCIXIMAB;

ANGIOGENESIS; B CELL LYMPHOMA; BINDING SITE; BLEEDING DISORDER; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENE THERAPY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; NONHUMAN; PROSTATE CANCER; PROTEINURIA; REVIEW; SOLID TUMOR; THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 28844431764     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.9.6.1235     Document Type: Review

References (91)

1. HOLLIGER P, HUDSON PJ: Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. (2005) 23:1126-1136.
2. CARTER P: Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer (2001) 1:118-129.
3. KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-497.
4. HUDSON PJ, SOURIAU C: Engineered antibodies. Nat. Med. (2003) 9:129-134.
5. REICHERT JM, ROSENSWEIG CJ, FADEN LB, DEWITZ MC: Monoclonal antibody successes in the clinic. Nat. Biotecbnol. (2005) 23:1073-1078.
6. SANZ L, BLANCO B, ÁLVAREZ-VALLINA L: Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol. (2004) 25:85-91.
7. CARMELIET P: Angiogenesis in health and disease. Nat. Med. (2003) 9:653-660.
8. CARMELIET P, JAIN RK: Angiogenesis in cancer and other diseases. Nature (2000) 407:249-257.
9. JAIN RK, SCHLENGER K, HOCKEL M, YUAN F: Quantitative angiogenesis assays: progress and problems. Nat. Med. (1997) 3:1203-1208.
10. FOLKMAN J: Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. (1971) 285:1182-1186.
11. LEUNG DW, CACHIANES G, KUANG WJ, GOEDDEL DV, FERRARA N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 246:1306-1309,
12. CARMELIET P, FERREIRA V, BREIER G et al.: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 380:435-439.
13. FERRARA N, GERBER HP, LECOUTER J: The biology of VEGF and its receptors. Nat. Med. (2003) 9:669-676.
14. KIM KJ, LI B, WINER J et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362:841-844.
15. PRESTA LG, CHEN H, O'CONNOR SJ et al.: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. (1997) 57:4593-4599.
16. KABBINAVAR F, HURWITZ HI, FEHRENBACHER L et al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. (2003) 21:60-65.
17. JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22:2184-2191.
18. YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349:427-434.
19. HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342.
20. SCAPPATICCI FA, FEHRENBACHER L, CARTWRIGHT T et al.: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol. (2005) 91:173-180.
21. SUGIMOTO H, HAMANO Y, CHARYTAN D et al.: Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt- 1) induces proteinuria. J. Biol. Chem. (2003) 278:12605-12608.
22. MILLER KD, CHAP LI, HOLMES FA et al.: Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. (2005) 23:792-799.
23. FERRARA N, HILLAN KJ, GERBER HP, NOVOTNY W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. (2004) 3:391-400.
24. TUMA RS: Success of bevacizumab trials raises questions for future studies. J. Natl. Cancer Inst. (2005) 97:950-951.
25. BREKKEN RA, OVERHOLSER JP, STASTNY VA et al.: Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Res. (2000) 60:5117-5124.
26. VITALITI A, WITTMER M, STEINER R et al.: Inhibition of tumor angiogenesis by a single-chain antibody directed against vascular endothelial growth factor. Cancer Res. (2000) 60:4311-4314.
27. AFANASIEVA TA, WITTMER M, VITALITI A et al.: Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy. Gene Ther. (2003) 10:1850-1859.
28. COOKE SP, BOXER GM, LAWRENCE L et al.: A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: receptor complex. Cancer Res. (2001) 61:3653-3659.
29. KUNKEL P, ULBRICHT U, BOHLEN P et al.: Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. (2001) 61:6624-6628.
30. PREWETT M, HUBER J, LI Y et al.: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. (1999) 59:5209-5218.
31. FENTON BM, PAONI SF, DING I: Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors. Cancer Res. (2004) 64:5712-5719.
32. RAKHMILEVICH AL, HOOPER AT, HICKLIN DJ, SONDEL PM: Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody. Mol. Cancer Ther. (2004) 3:969-976.
33. WANG ES, TERUYA-FELDSTEIN J, WU Y et al.: Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood (2004) 104:2893-2902.
34. VOSSELER S, MIRANCEA N, BOHLEN P, MUELLER MM, FUSENIG NE: Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res. (2005) 65:1294-1305.
35. ZHU Z, ROCKWELL P, LU D et al.: Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library. Cancer Res. (1998) 58:3209-3214.
36. ZHU Z, LU D, KOTANIDES H et al.: Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Lett. (1999) 136:203-213.
37. LU D, JIMENEZ X, ZHANG H et al.: Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res. (2001) 61:7002-7008.
38. POSEY JA, NG TC, YANG B et al.: A Phase I study of anti-kinase insert domain-containing receptor antibody, IMC, 1C11, in patients with liver metastases from colorectal carcinoma. Clin. Cancer Res. (2003) 9:1323-1332.
39. ZHU Z, HATTORI K, ZHANG H et al.: Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity. Leukemia (2003) 17:604-611.
40. LUTTUN A, TJWA M, MOONS L et al.: Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. (2002) 8:831-840.
41. JIMENEZ X, LU D, BRENNAN L et al.: A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol. Cancer Ther. (2005) 4:427-434.
42. HE Y, RAJANTIE I, PAJUSOLA K et al.: Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endotheliurn is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. (2005) 65:4739-4746.
43. POPKOV M, JENDREYKO N, MCGAVERN DB, RADER C, BARBAS CF, III: Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. Cancer Res. (2005) 65:972-981.
44. JENDREYKO N, POPKOV M, BEERLI RR et al.: Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J. Biol. Chem. (2003) 278:47812-47819.
45. JENDREYKO N, POPKOV M, RADER C, BARBAS CF, III: Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc. Natl. Acad. Sci. USA (2005) 102:8293-8298.
46. OLINER J, MIN H, LEAL J et al.: Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 6:507-516.
47. CAI M, ZHANG H, HUI R: Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro. Biochem. Biophys. Res. Commun. (2003) 309:946-951.
48. OVERALL CM, LOPEZ-OTIN C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer (2002) 2:657-672.
49. JOYCE JA, BARUCH A, CHEHADE K et al.: Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell (2004) 5:443-453.
50. ROUSSELET N, MILLS L, JEAN D et al.: Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res. (2004) 64:146-151.
51. BALBIN M, FUEYO A, TESTER AM et al.: Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat. Genet. (2003) 35:252-257.
52. STUPACK DG, CHERESH DA. ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Sci. STKE. (2002) 2002:E7.
53. CHERESH DA: Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor. Proc. Natl. Acad. Sci. USA (1987) 84:6471-6475.
54. BROOKS PC, STROMBLAD S, KLEMKE R et al.: Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest (1995) 96:1815-1822.
55. SIPKINS DA, CHERESH DA, KAZEMI MR et al.: Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat. Med. (1998) 4:623-626.
56. FRIEDLANDER M, BROOKS PC, SHAFFER RW et al.: Definition of two angiogenic pathways by distinct alpha v integrins. Science (1995) 270:1500-1502.
57. TRIKHA M, ZHOU Z, NEMETH JA et al.: CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer (2004) 110:326-335.
58. PARSONS-WINGERTER P. KASMAN IM, NORBERG S et al.: Uniform overexpression and rapid accessibility of alpha5betal integrin on blood vessels in tumors. Am. J. Pathol (2005) 167:193-211.
59. RAMAKRISHNAN V, BRASKAR V, LAW DA, WONG MHL: M200, an integrin alpha5beta1 antibody, promotes apoptosis in proliferating endothelial cells. 2004 ASCO Annual Meeting Proceedings. J. Clin. Oncol. (2004) 22:3187 (Abstract).
60. ISRAELI RS, POWELL CT, CORR JG, FAIR WR, HESTON WD: Expression of the prostate-specific membrane antigen. Cancer Res. (1994) 54:1807-1811.
61. CHANG SS, REUTER VE, HESTON WD et al.: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. (1999) 59:3192-3198.
62. LIU H, MOY P, KIM S et al.: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. (1997) 57:3629-3634.
63. MATSUNO F, HARUTA Y, KONDO M et al.: Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin. Cancer Res. (1999) 5:371-382.
64. TABATA M, KONDO M, HARUTA Y, SEON BK: Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies. Int. J. Cancer (1999) 82:737-742.
65. TAKAHASHI N, HABA A, MATSUNO F, SEON BK: Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res. (2001) 61:7846-7854.
66. NETTELBECK DM, MILLER DW, JEROME V et al.: Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol. Ther. (2001) 3:882-891.
67. KORN T, MULLER R, KONTERMANN RE: Bispecific single-chain diabody-mediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J. Immunother. (2004) 27:99-106.
68. BALZA E, CASTELLANI P, ZIJLSTRA A et al.: Lack of specificity of endoglin expression for tumor blood vessels. Int. J. Cancer (2001) 94:579-585.
69. COSTELLO B, LI C, DUFF S et al.: Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int. J. Cancer (2004) 109:436-441.
70. OH P, LI Y, YU J et al.: Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature (2004) 429:629-635.
71. ERICKSON AC, COUCHMAN JR: Still more complexity in mammalian basement membranes. J. Histochem. Cytochem. (2000) 48:1291-1306.
72. KALLURI R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer (2003) 3:422-433.
73. ST CROIX B, RAGO C, VELCULESCU V et al.: Genes expressed in human tumor endothelium. Science (2000) 289:1197-1202.
74. HALIN C, NERI D: Antibody-Based targeting of angiogenesis. Crit Rev. Ther. Drug Carrier Syst. (2001) 18:299-339.
75. CASTELLANI P, VIALE G, DORCARATTO A et al.: The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer (1994) 59:612-618.
76. BORSI L, BALZA E, CARNEMOLLA B et al.: Selective targeted delivery of TNFalpha to tumor blood vessels. Blood (2003) 102:4384-4392.
77. CARNEMOLLA B, BORSI L, BALZA E et al.: Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 99:1659-1665.
78. EBBINGHAUS C, RONCA R, KASPAR M et al.: Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int. J. Cancer (2005) 116:304-313.
79. HALIN C, RONDINI S, NILSSON F et al.: Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat. Biotechnol. (2002) 20:264-269.
80. NILSSON F, KOSMEHL H, ZARDI L, NERI D: Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res. (2001) 61:711-716.
81. BIRCHLER M, VITI F, ZARDI L, SPIESS B, NERI D: Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment. Nat. Biotechnol. (1999) 17:984-988.
82. SANTIMARIA M, MOSCATELLI G, VIALE GL et al.: Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. (2003) 9:571-579.
83. FUKUDA T, YOSHIDA N, KATAOKA Y et al.: Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly in vitro. Cancer Res. (2002) 62:5603-5610.
84. SANZ L, ÁLVAREZ-VALLINA L: The extracellular matrix: a new turn-of-the-screw for anti-angiogenic strategies. Trends Mol. Med. (2003) 9:256-262.
85. KLEINMAN HK, PHILP D, HOFFMAN MP: Role of the extracellular matrix in morphogenesis. Curr. Opin. Biotechnol. (2003) 14:526-532.
86. NOMIZU M, KURATOMI Y, SONG SY et al.: Identification of cell binding sequences in mouse laminin gamma1 chain by systematic peptide screening. J. Biol. Chem. (1997) 272:32198-32205.
87. WINTER G, GRIFFITHS AD, HAWKINS RE, HOOGENBOOM HR: Making antibodies by phage display technology. Ann. Rev. Immunol. (1994) 12:433-455.
88. SANZ L, KRISTENSEN P, RUSSELL SJ, RAMIREZ G, Jr., ÁLVAREZ-VALLINA L: Generation and characterization of recombinant human antibodies specific for native laminin epitopes: potential application in cancer therapy. Cancer Immunol. Immunother. (2001) 50:557-565.
89. SANZ L, KRISTENSEN P, BLANCO B et al.: Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene Ther. (2002) 9:1049-1053.
90. SANZ L, QIAO J, VILE RG, ÁLVAREZ-VALLINA L: Antibody engineering, virus retargeting and cellular immunotherapy: one ring to rule them all? Curr. Gene Ther. (2005) 5:63-70.
91. SANZ L, FEIJOO M, BLANCO B, SERRANO A, ÁLVAREZ-VALLINA L: Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells. Cancer Immunol. Immunother. (2003) 52:643-647.